Piperazine derivatives as HIV protease inhibitors

US10138255B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• MSD R&D (China) Co. Ltd. · CN

Inventors

• Peter D. Williams · Harleysville, US
• John A. McCauley · Maple Glen, US
• Christopher James Bungard · Lansdale, US
• David Jonathan Bennett · Watertown, US
• Sherman T. Waddell · Westfield, US
• Gregori J. Morriello · Dover, US
• Lehua Chang · Ramsey, US
• Michael P. Dwyer · Scotch Plains, US
• M. Katharine Holloway · Lansdale, US
• Alejandro Crespo · Edison, US
• Xin-Jie Chu · Livingston, US
• Catherine M. Wiscount · Allentown, US
• H. Marie Loughran · Perkasie, US
• Jesse J. Manikowski · Worcester, US
• Jürgen Schulz · Hamilton, GB
• Kartik M. Keertikar · Plainsboro, US
• Bin Hu · Mesa, US
• Bin Zhong · Shanghai, CN
• Tao Ji · Amherst, US

Key dates

• Filing date: Mar 6, 2015
• Grant date: Nov 27, 2018
• Expiry date: Mar 6, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/18
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.